A Transgenic Platform for Testing Drugs Intended for Reversal of Cardiac Remodeling Identifies a Novel 11βHSD1 Inhibitor Rescuing Hypertrophy Independently of Re-Vascularization

• Oren Gordon ,

  Contributed equally to this work with: Oren Gordon, Zhiheng He

  Affiliation Departments of Developmental Biology and Cancer Research, The Hebrew University–Hadassah University Hospital, Jerusalem, Israel

  ⨯
• Zhiheng He ,

  Contributed equally to this work with: Oren Gordon, Zhiheng He

  Affiliation Departments of Developmental Biology and Cancer Research, The Hebrew University–Hadassah University Hospital, Jerusalem, Israel

  ⨯
• Dan Gilon,

  Affiliation Department of Cardiology, The Hebrew University–Hadassah University Hospital, Jerusalem, Israel

  ⨯
• Sabine Gruener,

  Affiliation Department of Metabolic and Vascular Disease, Hoffmann-La Roche Pharmaceuticals, Basel, Switzerland

  ⨯
• Sherrie Pietranico-Cole,

  Affiliation Department of Metabolic and Vascular Disease, Hoffmann-La Roche Pharmaceuticals, Basel, Switzerland

  ⨯
• Amit Oppenheim,

  Affiliation Department of Cardiology, The Hebrew University–Hadassah University Hospital, Jerusalem, Israel

  ⨯
• Eli Keshet

  * E-mail: keshet@cc.huji.ac.il

  Affiliation Departments of Developmental Biology and Cancer Research, The Hebrew University–Hadassah University Hospital, Jerusalem, Israel

  ⨯